Key result
SynCardia TAH provides full heart replacement without immunosuppression in biventricular failure.
Population
Patients with biventricular failure / end-stage heart failure
Design
Review
Authors
Loading...
Supports immunosuppression-free TAH option in biventricular failure; leaves open long-term durability and adoption.
Total artificial hearts are evolving as a bridge-to-transplantation and potential long-term alternative for patients with end-stage biventricular failure.
Rubin et al. (2025) studied this question. The SynCardia temporary total artificial heart provides a full heart replacement option in biventricular failure patients without the need for immunosuppression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: